AWARD A LETTER CONTRACT FOR RADX TECH - OASIS DIAGNOSTICS TO COMPLETE THE VALIDATION, APPROVAL, AND PRODUCTION PROCESSES IN ORDER TO SCALE UP CAPACITY

Oasis Diagnostics提供一系列创新工具，用于标准化唾液采集，包括专门用于无细胞RNA /病毒RNA的设备，非常适合对困难的唾液样本进行COVID-19检测。特别是这些收集工具[pure<e:1>™™SAL、super<e:1>™sal<e:1>™、micro<e:2>™SAL和SimplOFy]与正在使用的测试无关，并且已经被许多开发基于口服/唾液的COVID-19测试的公司使用。Oasis是一家员工不到20人的小型企业，新冠病毒开发企业要求Oasis扩大生产规模，以便每天生产10万件以上的新冠病毒技术。为了能够实现这一目标，Oasis诊断公司需要额外的人力、设备和额外的资源，目前还没有这些资源。因此，Oasis正在通过RADx计划寻求资金，以促进大规模生产，以满足快速增长的唾液收集技术市场

Oasis Diagnostics provides a series of innovative tools for standardized saliva acquisition including devices specific for cell free RNA / viral RNA that are ideally suited for COVID-19 testing on difficult saliva specimens. These collection tools [Pure•SAL, Super•SALâ„¢, Micro•SAL and SimplOFy] in particular are agnostic to the test being used and are already being used by many companies developing oral / saliva based tests for COVID-19. Oasis is a small business with under 20 employees and has been requested by companies developing COVID-19 to scale up manufacturing in order to produce volumes in excess of 100,000 Units of these technologies on a daily basis.  In order to be able to meet this goal, Oasis Diagnostics requires additional manpower, equipment and additional resources that it does not have at the present time.  As a result Oasis is seeking funding through the RADx Program to facilitate large scale manufacturing to meet the rapidly growing market for saliva collection technologies